[Clinical efficiency of the anti-inflammatory anesthetic combination suxibuzone-N.A.P.A].
D000082:Acetaminophen / Q000008:administration & dosage* / Q000009:adverse effects; D000328:Adult; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage* / Q000009:adverse effects; D001168:Arthritis / Q000188:drug therapy*; D002214:Capsules; D002986:Clinical Trials as Topic; D004338:Drug Combinations; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007249:Inflammation / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010653:Phenylbutazone / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D013488:Suppositories; D014947:Wounds and Injuries / Q000188:drug therapy*
D000893:Anti-Inflammatory Agents; D002214:Capsules; D004338:Drug Combinations; D013488:Suppositories; D000082:Acetaminophen; D010653:Phenylbutazone
Eficacia clínica de la asociación antiinflamatoria analgésica suxibuzona-N.A.P.A.